Payment overview · 2025
General Payments
$168.98
9 reported records · 5 companies
Healthcare provider profile · identity verified
Edward John Knish, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MATTHEWS, NC · NPI 1356365878
Verified facts
What the public records show
CMS Open Payments records show Edward John Knish, MD received $168.98 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 36.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.17 | 36.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.70 | 23.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.07 | 17.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.01 | 12.4% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $17.03 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $168.98 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.70 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 483 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 453 | 110 |
| Omeprazole | Omeprazole | 413 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 116 |
| Lisinopril | Lisinopril | 363 | 102 |
| Lorazepam | Lorazepam | 275 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 78 |
| Metformin Hcl | Metformin Hcl | 248 | 73 |
| Gabapentin | Gabapentin | 246 | 68 |
| Simvastatin | Simvastatin | 246 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 69 |
| Losartan Potassium | Losartan Potassium | 226 | 65 |
| Tramadol Hcl | Tramadol Hcl | 222 | 58 |
| Alprazolam | Alprazolam | 221 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 202 | 34 |
| Trazodone Hcl | Trazodone Hcl | 181 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 49 |
| Meloxicam | Meloxicam | 152 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 33 |
| Sertraline Hcl | Sertraline Hcl | 146 | 39 |
| Furosemide | Furosemide | 144 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 43 |
| Bupropion Xl | Bupropion Hcl | 137 | 35 |
| Clonazepam | Clonazepam | 127 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 34 |
| Eliquis | Apixaban | 124 | 32 |
| Prednisone | Prednisone | 122 | 87 |
| Alendronate Sodium | Alendronate Sodium | 119 | 43 |
| Montelukast Sodium | Montelukast Sodium | 116 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 40 |
| Mirtazapine | Mirtazapine | 105 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 26 |
| Famotidine | Famotidine | 91 | 24 |
| Celecoxib | Celecoxib | 90 | 24 |
| Carvedilol | Carvedilol | 86 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 64 |
| Ozempic | Semaglutide | 86 | 16 |
| Allopurinol | Allopurinol | 85 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 24 |
| Metformin Hcl Er | Metformin Hcl | 77 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 20 |
| Ezetimibe | Ezetimibe | 71 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 17 |
| Glimepiride | Glimepiride | 66 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 61 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 22 |
| Potassium Chloride | Potassium Chloride | 57 | 22 |
| Finasteride | Finasteride | 54 | 17 |
| Benazepril Hcl | Benazepril Hcl | 53 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 16 |
| Buspirone Hcl | Buspirone Hcl | 49 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 19 |
| Fluconazole | Fluconazole | 47 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 11 |
| Synthroid | Levothyroxine Sodium | 46 | 14 |
| Jardiance | Empagliflozin | 44 | 11 |
| Atenolol | Atenolol | 42 | 12 |
| Cephalexin | Cephalexin | 42 | 33 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Lovastatin | Lovastatin | 40 | 11 |
| Diazepam | Diazepam | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 12 |
| Estradiol | Estradiol | 34 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 11 |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 27 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 17 |
| Valacyclovir | Valacyclovir Hcl | 27 | 17 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Amoxicillin | Amoxicillin | 25 | 16 |
| Azithromycin | Azithromycin | 25 | 21 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 21 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Euthyrox | Levothyroxine Sodium | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Oxazepam | Oxazepam | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Trandolapril | Trandolapril | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $168.98 · 9 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, ImmunoCAP, KRYSTEXXA, Ozempic, PREVNAR 20, Rybelsus, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error